ChemT Biotechnology Secures $5M to Scale AI-Driven Biomanufacturing

Biomanufacturing currently struggles with unpredictable yields and high costs, as manufacturers often lack the tools to precisely manipulate the cellular "factories" used to produce biologics. ChemT addresses these bottlenecks through its proprietary CelMo™ platform, which simulates how cells respond to stress and genetic changes. By mapping these internal biological processes, the system identifies pathways to improve manufacturing performance and designs small molecules to guide cell behavior.

Early performance metrics suggest significant gains: the platform has demonstrated a 50% increase in antibody output in CHO cells and a 40% reduction in production timelines. Its flagship product, Chemplify™, has shown even steeper improvements in T-cell manufacturing, including 10x higher cell expansion yields and 60% lower costs. With over 40 global commercial partnerships already established, ChemT intends to use the new funding to advance its products toward GMP standards and expand its AI capabilities into stem, NK, and HEK cell systems.